MYL-1402O: A Bevacizumab Biosimilar

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Bevacizumab is a key anti-vascular endothelial growth factor antibody used in treating various solid cancers, including non-small cell lung cancer (NSCLC).
• The development of biosimilars offers potential for increased patient access to effective biologic therapies.

Purpose of the Study:

• To evaluate MYL-1402O (Abevmy®, Lextemy®), a biosimilar of bevacizumab, for its efficacy, safety, tolerability, and immunogenicity.
• To confirm the clinical equivalence of MYL-1402O compared to the reference bevacizumab.

Main Methods:

• Physicochemical, pharmacodynamic, and pharmacokinetic similarity assessments between MYL-1402O and reference bevacizumab.
• Clinical efficacy evaluation in patients with non-squamous NSCLC.
• Comparative analysis of safety, tolerability, and immunogenicity profiles.

Main Results:

• MYL-1402O exhibits similar physicochemical and pharmacodynamic properties to reference bevacizumab.
• Pharmacokinetic similarity was demonstrated in healthy male subjects.
• Equivalent clinical efficacy was observed in patients with non-squamous NSCLC.
• Tolerability, safety, and immunogenicity profiles were consistent with reference bevacizumab.

Conclusions:

• MYL-1402O is a clinically effective biosimilar to bevacizumab with a comparable safety profile.
• MYL-1402O (Abevmy®, Lextemy®) provides a viable therapeutic option for patients requiring bevacizumab for approved indications, including NSCLC and other solid tumors.